Video

Dr. Pinilla-Ibarz on Choosing Second-line BTK Inhibitors in CLL

Javier Pinilla-Ibarz, MD, PhD, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia.

Javier Pinilla-Ibarz, MD, PhD, senior member, head of Lymphoma Section, Department of Malignant Hematology, Moffitt Cancer Center, discusses the factors that go into choosing the optimal second-line BTK inhibitors for patients with chronic lymphocytic leukemia (CLL).

Although second-generation BTK inhibitors generally elicit more durable responses, all BTK inhibitors, such as acalabrutinib (Calquence) and zanubrutinib (Brukinsa), have class effects, including bleeding and hypertension, Pinilla-Ibarz says. While the possibility for cardiovascular effects may make these second-generation BTK inhibitors seem suboptimal for certain high-risk patients, other drugs being investigated in CLL may still cause similar adverse effects (AEs) in longer follow-up, Pinilla-Ibarz notes.

Since AEs are a possibility with all BTK inhibitors, even well tolerated ones such as ibrutinib (Imbruvica), closely monitoring patients throughout treatment is important, Pinilla-Ibarz explains. Fortunately, patients with CLL have a variety of treatment options, and alternatives exist for those who respond poorly to certain agents, Pinilla-Ibarz concludes.

Related Videos
Tiago Biachi, MD, PhD
Dr Girard on De Novo and Acquired Resistance Alterations in HER2-Altered NSCLC
Elias Jabbour, MD
Daniel DeAngelo, MD, PhD
Douglas W. Sborov, MD, MS
Meletios (Thanos) Dimopoulos, MD, professor, therapeutics, Hematology Oncology, National and Kapodistrian University of Athens School of Medicine
Adam E. Singer, MD, PhD, Health Sciences Clinical Instructor, medicine, division lead, kidney cancer, Division of Hematology/Oncology, UCLA Health
Ami Umesh Badami, MD
Premal Thaker, MD, MS
Paul Chinfai Lee, MD, discusses the role of surgeons in regard to molecular testing in non–small cell lung cancer.